Previous Close | 2.3000 |
Open | 2.1600 |
Bid | 2.5100 x 900 |
Ask | 2.6300 x 800 |
Day's Range | 2.1600 - 2.3600 |
52 Week Range | 0.9600 - 3.8500 |
Volume | |
Avg. Volume | 29,386 |
Market Cap | 53.246M |
Beta (5Y Monthly) | 0.85 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8200 |
Earnings Date | May 14, 2024 - May 20, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.85 |
Subscribe to Yahoo Finance Plus to view Fair Value for NSPR
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript March 6, 2024 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.2. InspireMD, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to InspireMD Fourth Quarter and […]
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s C-GUARDIANS II clinical trial of its SwitchGuard™ NPS for Transcarotid Artery Revascularization (TCAR),
-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open. Management will host a conference call and webcast with the in